is this you? Claim your profile.
is this you? Claim your profile.
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
Frost & Sullivan Lauds Aptilonâ€™s Innovative Alternative Sales & Marketing Channel for the Healthcare
"Aptilon's creative alternative to traditional sales and marketing methods addresses this changing dynamic and makes it possible for companies to cost-effectively access "hard-to-see" or "no-see" healthcare professionals though Internet-enabled live video detailing and marketing presentations," says Frost & Sullivan Research Analyst Misty Hughes.
"Additionally, Aptilon's suite of web-based services offers healthcare providers one-stop shopping with options to participate in peer-education events, case study education and e-CME courses, as well as the ability to order patient education materials, samples, and vouchers," notes Hughes.
"OVATION has strategically concentrated its research efforts on developing treatments for the often overlooked rare and orphan disease market, avoiding many of the pitfalls other company's face when strictly pursuing blockbuster therapies and indications," says Frost & Sullivan Research Analyst Misty Hughes.
"Through selective partnerships and financial responsibility, OVATION, having justly labeled itself the 'Partner of Choice,' has built a solid organization with uniquely strong capabilities required for specialized therapies for rare diseases." Fueled by the desire to provide life-sustaining therapies for severely ill, vastly underserved patient populations, OVATION has applied its commercial, regulatory and manufacturing expertise to develop partnerships with top companies - Merck, Abbott Laboratories, Sanofi-Synthelabo, Aventis, among others - resulting in sustaining much-needed treatment options on the market, as well as building an enviable late-stage development pipeline. With a core focus on disorders of the central nervous system (CNS), hematology and oncology, neonatal intensive care (NIC), and hospital-based therapies, this company of nearly 300 industry professionals boasts a portfolio of 20 pharmaceutical products with sales in more than 85 countries worldwide, and a reported five year compound annual growth rate of 85 percent. "Many of OVATION's compounds acquired through partner company divestitures or out-license agreements are currently available and being successfully marketed, both locally and globally, or are in the late-stages of clinical trials for approval in the U.S.," says Hughes.
"Prelude SkinPrep overcomes the primary obstacle to achieving therapeutic drug levels via the transdermal route - the brick-and-mortar-like stratum corneum - making it possible to transdermally deliver a compound in a manner that preserves the integrity of the skin, reduces the risk of infection, and improves the quality of care," concluded Frost & Sullivan Research Analyst, Misty Hughes.
"Prelude SkinPrep overcomes the primary obstacle to achieving therapeutic drug levels via the transdermal route the brick-and-mortar-like stratum corneum - making it possible to transdermally deliver a compound in a manner that preserves the integrity of the skin, reduces the risk of infection, and improves the quality of care," concluded Frost & Sullivan Research Analyst, Misty Hughes.
Commenting on the selection of OVATION as this year's award winner, Frost & Sullivan Research Analyst Misty Hughes added, "Bypassing many of the pitfalls other companies encounter when strictly pursuing blockbuster indications, this pioneering company has, and continues to, achieve marked success researching and developing therapies for the often overlooked rare and orphan disease market."